Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [52]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Intestinal Epithelial Cell Surface Membrane Glycoprotein Synthesis
Weiser, M. M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44141-0 · Cited by 1,098
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936
Self-citationLost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Research works printed but not linked: 9
- Mariadason, 1997, Am. J. Physiol., 272, G705
- Heerdt, 1994, Cancer Res., 54, 3288
- Mei, 2004, Int. J. Oncol., 25, 1509
- Fischle, 2001, Biochem. Cell Biol., 79, 337, 10.1139/o01-116 · DOI · Paper page
- Mariadason, 2001, Cancer Res., 61, 3465
- Sowa, 1999, Cancer Res., 59, 4266
- Mariadason, 2003, Cancer Res., 63, 8791
- Yang, 2001, Cancer Res., 61, 565
- Bailey, 1999, Mol. Endocrinol., 13, 1155, 10.1210/mend.13.7.0305 · doi:10.1210/mend.13.7.0305 · Paper page
Cited by
Items 201–300 of 611
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
Hornig, E., Heppt, M. V., Graf, S. A., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13089 · Cited by 50
Sun, P., Wang, J., Khan, K. S., Yang, W., Ng, W., Ilment, N. V., Zessin, M., Bülbül, E. F., Robaa, D., Erdmann, F., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01132 · Cited by 51
Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
Elmallah, M. I. Y., & Micheau, O. (2019) · Cancers · doi:10.3390/cancers11060850 · Cited by 52
“Several studies have reported the overexpression of HDAC in different types of cancer such as HDAC1 in gastric [53], prostate [54], colon [55], and breast [56] cell carcinomas.”
BackgroundHistone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders
Gediya, P., Parikh, P. K., Vyas, V. K., & Ghate, M. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113332 · Cited by 54
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 46
“However, although there have been some reports of single HDAC inhibition affecting tumor cell growth as transient knockdown of HDAC1 or HDAC3 suppressed HeLa cell proliferation (20), another group showed that transient knockdown ofHDAC1, 2, or 3decreased the rate of proliferation of colon carcinoma cell lines (21).”
BackgroundFakih, M., Groman, A. E., McMahon, J., Wilding, G. E., & Muindi, J. R. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1762-1 · Cited by 46
Prasad, R., & Katiyar, S. K. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.52 · Cited by 45
“Several studies reported consistent overexpression of HDACs in colon, breast, prostate, lung, and other cancers [5-10].”
BackgroundKakiuchi, A., Kakuki, T., Ohwada, K., Kurose, M., Kondoh, A., Obata, K., Nomura, K., Miyata, R., Kaneko, Y., Konno, T., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.7997 · Cited by 49
By recruiting HDAC1, MORC2 suppresses p21Waf1/Cip1 in gastric cancer
Zhang, Q. H., Song, Y., Chen, W., Wang, X., Miao, Z., Cao, L., Feng, L., & Wang, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3889 · Cited by 44
“Here, we found that MORC2 repressed p21 expression and bound to the region (−114 bp to −62 bp) in the p21 promoter covering Sp1 sites, where HDAC1 was also bound to repress p21 expression [12, 15].”
Hrgović, I., Doll, M., Kleemann, J., Wang, X., Zöller, N. N., Pinter, A., Kippenberger, S., Kaufmann, R., & Meißner, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2807-y · Cited by 44
“Several studies indicated that p53 and Sp1/3 binding sites of the p21 promoter are critical for p21 induction by HDACi treatment [22–24].”
BackgroundSchmitt, H. M., Schlamp, C. L., & Nickells, R. W. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0059 · Cited by 44
“Additionally, HDAC3 inhibitors are being developed as anticancer agents,(39,40) although these effects may not necessarily be mediated directly on the cell cycle.(41) Since any treatment for a chronic neurodegenerative condition such as glaucoma will likely be long lasting, it will be important to monitor other tissue…”
BackgroundInfluence of the microbiota on epigenetics in colorectal cancer
Sun, D., Chen, Y., & Fang, J. (2018) · National Science Review · doi:10.1093/nsr/nwy160 · Cited by 46
“Their expressions were originally characterized in intestinal epithelial cells (IECs), and they play an important role in intestinal development and cancer [58,59].”
BackgroundSAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2)
Methot, J. L., Hamblett, C. L., Mampreian, D. M., Jung, J. O., Harsch, A., Szewczak, A. A., Dahlberg, W. K., Middleton, R. E., Hughes, B. L., Fleming, J. C., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.052 · Cited by 47
Fakih, M., Fetterly, G. J., Egorin, M. J., Muindi, J. R., Espinoza‐Delgado, I., Zwiebel, J. A., Litwin, A. M., Holleran, J. L., Wang, K., & Diasio, R. B. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0547 · Cited by 43
“HDAC1, HDAC2, and HDAC3 are overexpressed in colonic tumors, suggesting that HDAC may be an important target in the treatment of that disease.[4-6] The mechanisms of growth inhibition produced by HDAC inhibitors include effects on gene expression, cell cycle progression, and cell death pathways.”
BackgroundDeregulated expression of HDAC3 in colorectal cancer and its clinical significance
Nemati, M., Ajami, N., Estiar, M. A., Rezapour, S., Gavgani, R. R., Hashemzadeh, S., Kafil, H. S., & Sakhinia, E. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/66207 · Cited by 43
Ganai, S. A., Farooq, Z., Banday, S., & Altaf, M. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0020 · Cited by 44
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
Dejligbjerg, M., Grauslund, M., Litman, T., Collins, L. S., Qian, X., Jeffers, M., Lichenstein, H. S., Jensen, P., & Sehested, M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-70 · Cited by 48
Epigenetics in Intestinal Epithelial Cell Renewal
Roostaee, A., Benoit, Y. D., Boudjadi, S., & Beaulieu, J. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25401 · Cited by 51
“For instance, HDAC3 and HDAC4 which were both characterized as repressors of p21WAF1 expression in colorectal cancer cell lines have been reported to be predominantly expressed in the proliferative cells of the crypt in the normal intestine (Wilson et al., 2006, 2008).”
BackgroundExpression and role of nuclear receptor coregulators in colorectal cancer
Triki, M., Lapierre, M., Cavaillès, V., & Mokdad‐Gargouri, R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i25.4480 · Cited by 43
Xie, R., Li, Y., Tang, P., & Yuan, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.041 · Cited by 42
Xu, G., Zhu, H., Zhang, M., & Xu, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3225 · Cited by 45
“…cell cancer (42), prostate cancer (43) and pancreatic cancer (44), which was also observed in our study on Gc. a previous study pointed out that the knock-down of Hdac3 expression led to growth inhibition, an increase in apoptosis and a decrease in the survival of colon cancer cell lines (27).”
Targeting histone deacetylases for heart failure
Bush, E. W., & McKinsey, T. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902939161 · Cited by 43
“In various cancers, aberrant recruitment of class I HDACs to target gene promoters is thought to contribute to the inappropriate repression of tumor suppressors such as p21 [142-145].”
Colorectal Cancer: Pathogenesis and Targeted Therapy
Li, J., Pan, J., Wang, L., Ji, G., & Dang, Y. (2025) · MedComm · doi:10.1002/mco2.70127 · Cited by 57
“For instance, HDAC3 has been identified as a protein that is upregulated in colon cancer; its overexpression, along with other class I HDACs, suppresses the transcription of the cell cycle mediator p21 in a Sp1/Sp3-dependent manner [72].”
Histone deacetylases 1 and 2 are required for brain development
Jaworska, J., Ziemka‐Nałęcz, M., & Zalewska, T. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150071tz · Cited by 47
“In addition, HDACs control gene expression by regulating acetylation of DNA sequence-specific transcription factors (Wilson et al., 2006).”
BackgroundDecreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Jin, Z., Jiang, W., Jiao, F., Guo, Z., Hu, H. X., Wang, L., & Wang, L. (2014) · PubMed · Cited by 48
The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
Khabele, D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00111 · Cited by 42
“Our group and others have shown that targeting class I HDACs, particularly HDAC3, inhibits cellular proliferation and directly represses transcription of p21 (35, 36, 74, 75).”
BackgroundCrucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans
Lagger, S., Meunier, D., Mikula, M., Brunmeir, R., Schlederer, M., Artaker, M., Pusch, O., Egger, G., Hagelkrüys, A., Mikulits, W., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.264 · Cited by 42
“…in a variety of human cancers, including breast (Krusche et al, 2005), colon and colorectal (Giannini and Cavallini, 2005; Huang et al, 2005; Wilson et al, 2006; Ishihama et al, 2007; Weichert et al, 2008c; Thangaraju et al, 2009), endometrial (Weichert et al, 2008a), gastric (Choi et al,…”
BackgroundPeláez, I. M., Καλογεροπούλου, Μ., Ferraro, A., Voulgari, A., Pankotai, T., Boros, I., & Pintzas, A. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.024 · Cited by 40
“Preferential deacetylation f H3K9 has been reported for HDAC1 and HDAC3 in knock-down xperiments (Zhang et al., 2004) while growth reduction was bserved after knock-down of these enzymes in several colon caner cell lines (Wilson et al., 2006; Zhu et al., 2004; Spurling et al., 008).”
BackgroundGanai, S. A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.022 · Cited by 41
Shindoh, N., Mori, M., Terada, Y., Oda, K., Amino, N., Kita, A., Taniguchi, M., Sohda, K., Nagai, K., Sowa, Y., et al. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.545 · Cited by 39
“Up-regulated expression of HDAC1, HDAC2 and HDAC3 has been reported in human colon tumors (3-5).”
BackgroundMethodSelf-citationRahman, R., Osteso-Ibáñez, T., Hirst, R. A., Levesley, J., Kilday, J., Quinn, S., Peet, A. C., O’Callaghan, C., Coyle, B., & Grundy, R. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0272 · Cited by 40
“Copyright © 2010 American Association for Cancer Research are under pre-clinical and clinical investigation as viable anticancer agents (9-16).”
Uba, A. İ., & Yelekçi, K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1384402 · Cited by 43
“High expression of HDAC3 and other class-I HDACs in colon cancer is associated with deregulation of p21expression (Spurling et al., 2008; Wilson et al., 2006).”
BackgroundChoi, S.-W., & Friso, S. (2009) · CRC Press eBooks · doi:10.1201/9781420063561 · Cited by 39
Metal-dependent Deacetylases: Cancer and Epigenetic Regulators
López, J. E., Sullivan, E. D., & Fierke, C. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01067 · Cited by 37
Kumbhar, N., Nimal, S., Barale, S. S., Kamble, S. A., Bavi, R., Sonawane, K. D., & Gacche, R. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-05698-7 · Cited by 41
Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates
Bouyahya, A., Hachlafi, N. E., Aanniz, T., Bourais, I., Mechchate, H., Benali, T., Shariati, M. A., Burkov, P., Lorenzo, J. M., Wilairatana, P., et al. (2022) · Molecules · doi:10.3390/molecules27082568 · Cited by 42
“Knockdown of HDAC3 induced gathering of cells at the G2/M phase [103], whereas in osteosarcoma cells, this effect causes siRNA-mediated HDAC1 depletion [129].”
BackgroundRecent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
Patel, P., Wahan, S. K., Vishakha, S., Kurmi, B. D., Gupta, G. D., Rajak, H., & Asati, V. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220624090542 · Cited by 39
Histone Deacetylation: An Attractive Target for Cancer Therapy?
Al-Janadi, A., Chandana, S. R., & Conley, B. A. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00003 · Cited by 39
Sun, W., Zhou, X., Zheng, J., Lu, M., Nie, J.-Y., Yang, X., & Zheng, Z. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr113 · Cited by 42
Biomarkers of genome instability and cancer epigenetics
Reis, A. H. O., Vargas, F. R., & Lemos, B. (2016) · Tumor Biology · doi:10.1007/s13277-016-5278-5 · Cited by 43
“In cancers, HDAC1 appears to be overexpressed in prostate, gastric, lung, esophageal, colon, and breast cancers [74–77], HDAC2 appears overexpressed in colorectal, cervical, and gastric cancers [78–80], HDAC3 is overexpressed in gastric, prostate, and colorectal cancer [81, 82], while HDAC6 is overexpressed in breast…”
BackgroundAlcarraz‐Vizán, G., Boren, J., Lee, W. P., & Cascante, M. (2010) · Metabolomics · doi:10.1007/s11306-009-0192-0 · Cited by 38
“These effects should be applied to other cell lines that do respond to butyrate treatment, as HCT116 or CaCo-2 (Wilson et al. 2006).”
BackgroundBirkenkamp‐Demtröder, K., Mansilla, F., Sørensen, F. B., Kruhøffer, M., Cabezón, T., Christensen, L. L., Aaltonen, L. A., Verspaget, H. W., & Orntoft, T. F. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.05.005 · Cited by 44
“Our own transcript profiling studies showed that HDAC3 is highly expressed in all three cell lines and slightly upregulated in both MSS and MSI tumors ( p ¼ 5.3E-4) compared to normal mucosa, while the CDKN1A transcript was slightly downregulated in MSS tumors ( p ¼ 3.8E-5) (data not shown).”
Min, S. K., Koh, Y. H., Park, Y., Kim, H. J., Seo, J., Park, H., Cho, S. J., & Kim, I. S. (2012) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2012.46.2.142 · Cited by 35
“Age (yr)a 61 (15-96) 50 (25-81) 58 (32-92) Sex (M : F) 41 : 37 8 : 5 7 : 6 Follow-up (mo)a 31 (1-162) 18 (2-64) 15.”
Sobolewski, C., Sanduja, S., Blanco, F. F., Hu, L., & Dixon, D. A. (2015) · Biomolecules · doi:10.3390/biom5032035 · Cited by 35
“However, histone deacetylases (HDACs) promote transcriptional repression and have been associated with silencing of many tumor suppressor genes, since many HDACs are overexpressed in cancer [15,18].”
BackgroundHe, P., Li, K., Li, S.-B., Hu, T., Guan, M., Sun, F., & Liu, W.-W. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4284 · Cited by 38
“The overexpression of HDAC3 reportedly has the capability to inhibit basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas the silencing of HDAC3 stimulates p21 promoter activity and expression (32).”
BackgroundPatel, M. M., & Patel, B. M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.05.026 · Cited by 37
Saha, B., & Parks, R. J. (2019) · Journal of Virology · doi:10.1128/jvi.00088-19 · Cited by 39
“Since HDACs typically repress p21 expression (52), Hoti et al.”
BackgroundZinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension
Kee, H. J., Kim, I., & Jeong, M. H. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115111 · Cited by 41
Lee, C., Yao, C., Huang, S., Ko, S., Tan, Y. C., Lee‐Chen, G., & Wang, Y. (2008) · Cancer · doi:10.1002/cncr.23619 · Cited by 35
“It is noteworthy that we also found that 3-indole caused a reduction in expression of the histone deacetylase 1 (HDAC1), which highly expresses and correlates with proliferative status in a variety of cancer cells.(22,23) HDAC1 has been identified as a potential target for cancer treatment.”
Yu, C.-C., Pan, S., Chao, S.-W., Liu, S., Hsu, J., Yang, Y. S. H., Li, T., Huang, W., & Guh, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.001 · Cited by 36
Huang, H.-L., Lee, H., Tsai, A.-C., Peng, C.-Y., Lai, M.-J., Wang, J.-C., Pan, S., Teng, C., & Liou, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043645 · Cited by 35
“Class I HDACs have been shown to be overexpressed in human colorectal cancer cells [19], which may contribute to perturbed cancer cell proliferation, differentiation, and apoptosis by both epigenetic or non-epigenetic modification [20,21].”
BackgroundKong, L. R., Tan, T. Z., Ong, W. R., Bi, C., Huynh, H. T., Lee, S. C., Chng, W. J., Eichhorn, P. J. A., & Goh, B. C. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12064 · Cited by 34
“…which permits use, distribution and reproduction in any medium, provided the original work is properly cited. of HDAC1 have shown that loss of HDAC1 expression blocked mitosis in tumor cells (Senese et al., 2007), while HDAC3 silencing reduces the growth of colon cancer cells (Wilson et al., 2006).”
BackgroundSchmitt, F., Gosch, L. C., Dittmer, A., Rothemund, M., Mueller, T., Schobert, R., Biersack, B., Volkamer, A., & Höpfner, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020383 · Cited by 34
Wu, S., Jan, Y., Tsai, S., Pan, H.-C., Shen, C.-C., Yang, C.-N., Lee, S.-H., Liu, S., Shen, L., Chiu, C., et al. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09673-2 · Cited by 36
HDAC2 Promotes eIF4E Sumoylation and Activates mRNA Translation Gene Specifically
Xu, X. M., Vatsyayan, J., Gao, C., Bakkenist, C. J., & Hu, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.131599 · Cited by 36
Post-Translational Control of Sp-Family Transcription Factors
Waby, J. S., Bingle, C. D., & Corfe, B. M. (2008) · Current Genomics · doi:10.2174/138920208785133244 · Cited by 35
“Specific silencing of each of HDAC1, HDAC2 or HDAC3 using siRNA resulted in increased p21 promoter activity and expression in an Sp3-dependent manner, suggesting that increased acetylation caused increased activation of Sp3 controlled genes [29].”
BackgroundChromatin‐modifying proteins in cancer
Fog, C. K., Jensen, K. T., & Lund, A. H. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_776.xml.x · Cited by 37
Wang, L., Liou, J., Li, Y.-H., Liu, Y.-M., Pan, S., & Teng, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2155 · Cited by 33
“Considerable evidence shows that that knockdown of class I HDACs 1 and 2 inhibits cell growth and survival in various colon cancer cell lines [5-7].”
Schizas, D., Mastoraki, A. T., Naar, L., Tsilimigras, D. I., Katsaros, I., Fragkiadaki, V., Karachaliou, G. S., Arkadopoulos, N. F., Liakakos, T., & Moris, D. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190712160842 · Cited by 36
Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?
Avcı, E., Sarvari, P., Savai, R., Seeger, W., & Pullamsetti, S. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010546 · Cited by 37
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells
Mologni, L., Cleris, L., Magistroni, V., Piazza, R., Boschelli, F., Formelli, F., & Gambacorti-Passerini, C. B. (2008) · International Journal of Cancer · doi:10.1002/ijc.24158 · Cited by 39
“Indeed, HDACs 1, 2 and 3 have been shown to be overexpressed in CRC cells.(10,11) In particular, HDAC2 aberrant expression is induced by loss of the adenomatosis polyposis coli (APC) tumor suppressor and blockage of HDAC2 expression causes cell death, indicating a role for HDAC2 in protecting cancer cells against apop…”
BackgroundButyrate Increases GLUT2 mRNA Abundance by Initiating Transcription in Caco2‐BBe Cells
Mangian, H. F., & Tappenden, K. A. (2009) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607109336599 · Cited by 36
Uehara, N., Kanematsu, S., Miki, H., Yoshizawa, K., & Tsubura, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.032 · Cited by 33
Langer, R., Mutze, K., Becker, K., Feith, M., Ott, K., Höfler, H., & Keller, G. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.080952 · Cited by 34
“In the recent past, the inhibition of HDAC by siRNA knockdown”
BackgroundRoles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
Kwon, D., Ryu, J., Kim, Y., & Kook, H. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093246 · Cited by 34
Na, Y.-S., Jung, K., Kim, S.-M., Hong, Y. S., Ryu, M., Jang, S. J., Moon, D. H., Cho, D., Kim, J. C., Lee, J. S., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1495-6 · Cited by 36
Kim (2009) · International Journal of Oncology · doi:10.3892/ijo_00000483 · Cited by 31
Kasap, E., Gerçeker, E., Boyacıoğlu, S., Yüceyar, H., Yıldırm, H., Ayhan, S., & Korkmaz, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4131-6 · Cited by 32
“Recent studies indicate that histone modification genes including NEK6, AURKA, PAK1, HDAC1, HDAC2, HDAC3, HDAC5, and HDAC7 have key roles in the carcinogenesis of CRC [8–16].”
BackgroundConcept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
Schizas, D., Mastoraki, A. T., Naar, L., Spartalis, E. D., Tsilimigras, D. I., Karachaliou, G. S., Bagias, G., & Moris, D. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i41.4635 · Cited by 35
Ouaïssi, M., Silvy, F., Sofia, C. L., Giger-Pabst, U., Kevin, Z., Sastre, B., Sielezneff, I., Cordeiro‐da‐Silva, A., Lombardo, D., Mas, E., et al. (2012) · Pancreatology · doi:10.1016/j.pan.2012.02.013 · Cited by 34
Hecker, R., Amstutz, R., Wachtel, M., Walter, D., Niggli, F. K., & Schäfer, B. W. (2010) · Oncogene · doi:10.1038/onc.2010.145 · Cited by 37
“One very prominent effect observed for a large panel of HDAC inhibitors is induction of p21 (Sowa et al., 1997; Archer et al., 1998; Kim et al., 2001; Wilson et al., 2006).”
BackgroundWang, X., Wang, Y., Snitow, M. E., Stewart, K. M., Li, S., Lu, M., & Morrisey, E. E. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.04.023 · Cited by 33
“Histone deacetylases (HDACs) have been linked to cell cycle control in various model systems, involving regulation of the cyclin-dependent kinase inhibitors (Wilson et al., 2006; Yamaguchi et al., 2010).”
BackgroundMai, A., Perrone, A., Nebbioso, A., Rotili, D., Valente, S., Tardugno, M., Massa, S., Bellis, F. D., & Altucci, L. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.055 · Cited by 31
Gerçeker, E., Boyacıoğlu, S., Kasap, E., Baykan, A. R., Yüceyar, H., YILDIRIM, H., Ayhan, S., Ellidokuz, E., & Korkmaz, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4187 · Cited by 32
Singh, B. N., Zhou, H., Li, J., Tipton, T., Wang, B., Shao, G., Gilbert, E. N., Li, Q., & Jiang, S. (2011) · Future Oncology · doi:10.2217/fon.11.124 · Cited by 30
“HDAC3 is a component of the NCoR–SMRT corepressor complex, which is distinct from corepressor complexes that typically contain HDAC1 and HDAC2 [46].”
BackgroundCompetitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Su, H. L., Altucci, L., & You, Q. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2289 · Cited by 30
Apuri, S., & Sokol, L. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1164140 · Cited by 32
Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance
Kwon, Y., Kim, Y., Jung, H. S., & Jeoung, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010051 · Cited by 31
“Overexpression of HDAC3 in colorectal cancer cells is known to decrease expression of p21 [16].”
BackgroundEmerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response
Lee, R. S., Sad, K., Fawwal, D. V., & Spangle, J. M. (2023) · Cancers · doi:10.3390/cancers15154005 · Cited by 33
Laurenzana, A., Balliu, M., Cellai, C., Romanelli, M. N., & Paoletti, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058267 · Cited by 30
“[12,13], breast [14] and prostate [15,16,17].”
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Pchejetski, D., Alfraidi, A., Sacco, K. A., Alshaker, H. A., Muhammad, A., & Monzon, L. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2064-5 · Cited by 30
“Increased expression of HDAC1 has been found in gastric cancers, oesophageal squamous cell carcinoma, hormone-refractory prostate cancer, and colon cancer (Choi et al. 2001; Wilson et al. 2006).”
BackgroundSferra, R., Pompili, S., Festuccia, C., Marampon, F., Gravina, G. L., Ventura, L., Cesare, E. D., Cicchinelli, S., Gaudio, E., & Vetuschi, A. (2017) · European Journal of Histochemistry · doi:10.4081/ejh.2017.2732 · Cited by 31
Ocasio, C. A., Sansook, S., Jones, R. N., Roberts, J. M., Scott, T. G., Tsoureas, N., Coxhead, P., Guille, M., Tizzard, G. J., Coles, S. J., et al. (2017) · Organometallics · doi:10.1021/acs.organomet.7b00437 · Cited by 31
Rönsch, K., Jäger, M., Schöpflin, A., Danciu, M., Laßmann, S., & Hecht, A. (2011) · Epigenetics · doi:10.4161/epi.6.5.15300 · Cited by 28
“Changes in HAT activity due to mutations are known to play a role in certain forms of leukemia, whereas in epithelial cancers, HDACs feature more prominently.(22,33,36,37,45) The results of our inhibitor studies clearly reveal the repressive influence of class I and class III HDACs on CDX1, EPHB2 and EPHB3.”
BackgroundTargeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
Beljkaš, M., Ilić, A., Čebzan, A., Radović, B., Djoković, N., Ružić, D., Nikolic, K. M., & Oljačić, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15112581 · Cited by 33
Sholler, G. L. S., Currier, E. A., Dutta, A., Slavik, M. A., Illenye, S., Mendonça, M. C., Dragon, J. A., Roberts, S. S., & Bond, J. P. (2013) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-2-21 · Cited by 29
“These compounds are actively being studied in numerous cancers [8-12].”
Discovery and Mechanism of Natural Products as Modulators of Histone Acetylation
Salvador, L. A., & Luesch, H. (2012) · Current Drug Targets · doi:10.2174/138945012802008973 · Cited by 32
Zhu, J., Wan, H., Xue, C., Jiang, T., Qian, C., & Zhang, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.061 · Cited by 27
“It has been proposed that cancer stem cells (CSCs) are responsible for tumor initiation, resistance to therapeutics and tumor recurrence.”
InfluentialPadige, G., Negmeldin, A. T., & Pflum, M. K. H. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115598118 · Cited by 28
Ahmad, M., Hamid, A., Hussain, A., Majeed, R., Qurishi, Y., Bhat, J. A., Najar, R. A., Qazi, A. K., Zargar, M. A., Singh, S. K., et al. (2012) · DNA and Cell Biology · doi:10.1089/dna.2011.1575 · Cited by 30
“[ HDAC 2 and HDAC 3 Colon cancer Wilson et al. (2006)”
Bu, Q., Cui, L., Li, J., Du, X., Zou, W., Ding, K., & Pan, J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28931 · Cited by 28
Zhang, Y., Feng, J., Jia, Y., Xu, Y., Liu, C., Fang, H., & Xu, W. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.045 · Cited by 27
How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot
Beyer, M., Kiweler, N., Mahboobi, S., & Krämer, O. H. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_26 · Cited by 28
Enzyme-activated prodrugs and their release mechanisms for the treatment of cancer
Li, X., Huo, F., Zhang, Y., Cheng, F., & Yin, C. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00922f · Cited by 28
Omari, N. E., Bakrim, S., Khalid, A., Abdalla, A. N., Almalki, W. H., Lee, L., Ardianto, C., Ming, L. C., & Bouyahya, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114886 · Cited by 28
Adikesavan, A. K., Karmakar, S., Pardo, P. S., Wang, L., Liu, S., Li, W., & Smith, C. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01216-13 · Cited by 28
“Finally, to determine if SMRT interacts with p53 in vitro, GST pulldown assays employing 35S-labeled full-length SMRT protein produced in an in vitro translation system and bacterially expressed and purified recombinant GST-p53 protein were performed.”
BackgroundInfluentialIdentification of Histone Deacetylase 1 Protein Complexes in Liver Cancer Cells
Farooq, M., Hozzein, W. N., Elsayed, E. A., Taha, N. A., & Wadaan, M. A. M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.2.915 · Cited by 28
“HDAC1 is overexpressed in prostate, gastric, colon and breast carcinomas (Halkidou et al., 2004; Zhang et al., 2005; Wilson et al., 2006; Nakagawa et al., 2007).”
BackgroundAn HDAC-Targeted Imaging Probe LBH589–Cy5.5 for Tumor Detection and Therapy Evaluation
Meng, Q., Liu, Z., Li, F., Ma, J., Wang, H., Huan, Y., & Li, Z. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00167 · Cited by 26
Zou, Y., Howell, G. M., Humphrey, L. E., Wang, J., & Brattain, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069992 · Cited by 25
Metadata
- Authors
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Kyoto Prefectural University of Medicine (JP)
- Vall d'Hebron Institut de Recerca (ES)
- Corresponding author
- Mariadason, John M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 19
- Pages
- 13548-13558
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105095164
- Semantic Scholar
- c2db47db00c10ecf03aae7c6c6f1c3b194c81502
- Cited by
- 575
- References
- 43
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 31 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 30 · 2016: 30 · 2015: 38 · 2014: 32 · 2013: 40 · 2012: 28
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5273 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088104, R01CA100823, CA88104-04, CA100823-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, class I HDACs, colon cancer, histone deacetylase inhibitors, apoptosis, alkaline phosphatase, duodenal adenoma, crypt cells, gene silencing, tumor suppressor
- MeSH terms
- Cell Differentiation, Colon, Colonic Neoplasms, Histone Deacetylases, Humans, Time Factors, Down-Regulation, Up-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, Caco-2 Cells, Gene Silencing, HCT116 Cells, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.